Possis to Release Second Quarter Results on February 20
February 13 2008 - 8:00AM
Business Wire
Possis Medical, Inc. (NASDAQ: POSS), a developer, manufacturer and
distributor of pioneering medical devices used in endovascular
procedures, announced today that it will report complete results
for its second quarter ended January 31, 2008, at 7:00 a.m. (CT) on
Feb. 20, 2008. Based on preliminary results, Possis indicated that
it currently expects net sales of approximately $20.6 million for
the second quarter, a 30 percent increase from fiscal 2007
second-quarter sales of $15.8 million. In its outlook issued on
Nov. 21, 2007, the Company had estimated second-quarter net sales
of $18.7 million to $19.2 million. Possis anticipates second
quarter net income to fall within its previously issued guidance
range of $0.03 to $0.05 per diluted share, compared to a net loss
of $0.04 per diluted share in the second quarter of fiscal 2007.
The full release at 7:00 a.m. (CT) on February 20 will include
summary financial information for Possis� second quarter. Possis
will hold a shareholder conference call on Wednesday, Feb. 20,
2008, beginning at 9:30 a.m. (CT). Management will review
second-quarter financial and operating results, and discuss its
future outlook. To join the conference call, dial 1-800-762-8779
(international 1-480-248-5081). A replay of the conference call
will be available one hour after the call ends through 11:59 P.M.
(CT) on Feb. 22, 2008. To access the replay, dial 1-800-406-7325
(international 1-303-590-3030) and use the access code 3804797. For
individual investors, a Webcast of the conference call will be
available at www.possis.com under the "Investors" tab, or at
www.fulldisclosure.com. Institutional investors can access the
Webcast through a password-protected site at www.streetevents.com.
An archived Webcast of Possis� conference call will be available
for 30 days. About Possis Medical, Inc. Possis Medical, Inc.,
develops, manufactures and markets pioneering medical devices for
the large and growing cardiovascular and vascular treatment
markets. The company's AngioJet� System is the world's leading
mechanical thrombectomy system with FDA approval to remove large
and small thrombus from coronary arteries, coronary bypass grafts,
peripheral arteries and veins, A-V grafts and native fistulas.
Certain statements in this press release constitute
"forward-looking statements" within the meaning of Federal
Securities Laws. These statements are based on our current
expectations and assumptions, and entail various risks and
uncertainties that could cause actual results to differ materially
from those expressed in such forward-looking statements. A
discussion of these and other factors that could impact the
Company's future results are set forth in the cautionary statements
included in the Company's Form 10-K for the year ended July 31,
2007, filed with the Securities and Exchange Commission.
Possis Medical (MM) (NASDAQ:POSS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Possis Medical (MM) (NASDAQ:POSS)
Historical Stock Chart
From Aug 2023 to Aug 2024